Product description : (Osimertinib)Tagrix Osimertinib (Tagrix) is the 1st and only drug of its kind approved by USFDA for the treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell Lung Cancer (NSCLC) patient with T790M mutation. Therapeut
Product Features:
| Product Name | :Tagrix |
| Generic Name | : Osimertinib |
| Formulation | : Tablet |
| Available Pack Size | : 30’s |
| Available Strengths | : 40mg & 80mg |
| Registrations | : Bangladesh |
